Goldman Sachs Group Inc Entrada Therapeutics, Inc. Call Options Transaction History
Goldman Sachs Group Inc
- $605 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TRDA
# of Institutions
101Shares Held
28.1MCall Options Held
34.5KPut Options Held
16.4K-
Baker Bros. Advisors LP New York, NY4.87MShares$87.2 Million0.83% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.43MShares$79.4 Million48.7% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.41MShares$79 Million28.09% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.05MShares$54.7 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X01.71MShares$30.7 Million0.01% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $562M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...